Enbrel All Financial Data in US $ (mln)
Worldwide
 
Overview
 

Word Search (Top 10 - by date)

Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Pfizer (April 22, 2014)
Vas Narasimhan to Lead Sandoz’ Biosimilars Business
Novartis (March 27, 2014)
Sandoz Receives Approval for Biosimilar Filgrastim in Japan
Novartis (March 24, 2014)
Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Pfizer (March 22, 2014)
New Phase III Psoriasis Data Show Rapid, Significant Skin Clearance and Convenient Administration with Novartis' Secukinumab (AIN457)
Novartis (March 22, 2014)
Novartis Announces Start of New Secukinumab (AIN57) Versus Stelara® (ustekinumab) Phase IIIb Head-to-head Psoriasis Study at AAD 2014
Novartis (March 21, 2014)
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
Pivotal Therapeutics (March 10, 2014)
Tekmira Announces New Appointment to Board of Directors
Tekmira Pharmaceuticals (February 12, 2014)
Summary of Financial Statements for the Nine Month Period Ended December 31, 2013 (Japan GAAP, Consolidated)
Takeda (February 05, 2014)
Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
Amgen (January 28, 2014)

Displaying 10 out of a possible 594 unique stories.
Results Sorted By date
Display All Stories


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Enbrel
Generic Name:   etanercept
Therapeutic Subcategory:     Other anti-rheumatics
Therapeutic Subcategory:     Anti-virals

Product Sales Summary 2009/10

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2010
Enbrel2 7,257

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Enbrel3 381

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Enbrel

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now